← Leaderboards
Philip W Hinds
Harvard University (Medical School)
$12,088,422
Attributed
$13,123,719
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2005–15$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$13,123,719 · 8
By mechanism
R01$13,123,719 · 8
Top collaborators
- Lauren D. Black4 shared
- Gordon S Huggins4 shared
Others in their field
Top investigators on “Tumor Suppressor Proteins”
- Scott W Lowe · Sloan-Kettering Inst Can Research$30,621,807
- Carol Prives · Icahn School Of Medicine At Mount Sinai$25,974,663
- Pier Paolo Pandolfi · Sloan-Kettering Institute For Cancer Res$25,707,040
- Xinbin Chen · Medical College Of Georgia (Mcg)$23,449,975
- Carlo M Croce · Thomas Jefferson University$21,878,300
- Wei Gu · Columbia University Health Sciences$21,628,257
Research focus
Tumor Suppressor ProteinsCell CycleProteinsGrowthTumorigenesisCellsTumorPathway InteractionsPhenotypeMediatingEventGenesNeoplastic CellResearch StudyGene ExpressionPromotor (Genetics)BiologicalPhosphorylationProgramsPropertyIn VivoDesignCell ProliferationOncogenes
Grant awards (44)
Basic Mechanisms of Human Calcific Aortic Valve Disease$386,651
R01 · FY2015 · HL
Basic Mechanisms of Human Calcific Aortic Valve Disease$384,793
R01 · FY2014 · HL
Basic Mechanisms of Human Calcific Aortic Valve Disease$373,899
R01 · FY2013 · HL
CDK6 in T cell development and cancer$304,610
R01 · FY2013 · CA · contact PI
Basic Mechanisms of Human Calcific Aortic Valve Disease$407,602
R01 · FY2012 · HL
CDK6 in T cell development and cancer$324,053
R01 · FY2012 · CA · contact PI
Role of pRb in Osteogenesis, Cell Cycle Exit and Cancer$363,044
R01 · FY2011 · AG · contact PI
CDK6 in T cell development and cancer$324,053
R01 · FY2011 · CA · contact PI
Role of pRb in Osteogenesis, Cell Cycle Exit and Cancer$366,698
R01 · FY2010 · AG · contact PI
CDK6 in T cell development and cancer$334,075
R01 · FY2010 · CA · contact PI
Regulation and function of cdk5 and ezrin in senescence$249,738
R01 · FY2010 · CA · contact PI
Regulation and function of cdk5 and ezrin in senescence$95,157
R01 · FY2010 · CA · contact PI
Role of pRb in Osteogenesis, Cell Cycle Exit and Cancer$359,614
R01 · FY2009 · AG · contact PI
CDK6 in T cell development and cancer$334,075
R01 · FY2009 · CA · contact PI
Genetics of RAS, PTEN, BRAF and CDKN2A in Melanoma$274,719
R01 · FY2009 · CA · contact PI
Regulation and function of cdk5 and ezrin in senescence$249,738
R01 · FY2009 · CA · contact PI
Regulation and function of cdk5 and ezrin in senescence$92,819
R01 · FY2009 · CA · contact PI
CDK6 in T cell development and cancer$38,160
R01 · FY2009 · CA · contact PI
Cell Cycle Dysregulation in Oral Cancer$474,445
R01 · FY2008 · DE · contact PI
Role of pRb in Osteogenesis, Cell Cycle Exit and Cancer$349,138
R01 · FY2008 · AG · contact PI
Genetics of RAS, PTEN, BRAF and CDKN2A in Melanoma$274,719
R01 · FY2008 · CA · contact PI
Regulation and function of cdk5 and ezrin in senescence$249,738
R01 · FY2008 · CA · contact PI
Regulation and function of cdk5 and ezrin in senescence$88,269
R01 · FY2008 · CA · contact PI
Cell Cycle Dysregulation in Oral Cancer$458,345
R01 · FY2007 · DE · contact PI
Role of pRb in Osteogenesis, Cell Cycle Exit and Cancer$345,888
R01 · FY2007 · AG · contact PI
Genetics of RAS, PTEN, BRAF and CDKN2A in Melanoma$274,719
R01 · FY2007 · CA · contact PI
Regulation and function of cdk5 and ezrin in senescence$249,738
R01 · FY2007 · CA · contact PI
Cell Cycle Dysregulation in Oral Cancer$451,024
R01 · FY2006 · DE · contact PI
Role of pRb in Osteogenesis, Cell Cycle Exit and Cancer$316,386
R01 · FY2006 · AG · contact PI
Proliferative effects of cdk4 and cdk6 dysregulation$276,838
R01 · FY2006 · CA · contact PI
Regulation and function of cdk5 and ezrin in senescence$257,464
R01 · FY2006 · CA · contact PI
Cell Cycle Dysregulation in Oral Cancer$442,039
R01 · FY2005 · DE
Role of pRb in Osteogenesis, Cell Cycle Exit and Cancer$324,000
R01 · FY2005 · AG
Proliferative effects of cdk4 and cdk6 dysregulation$283,500
R01 · FY2005 · CA
Cell Cycle Dysregulation in Oral Cancer$423,966
R01 · FY2004 · DE
Role of pRb in Osteogenesis, Cell Cycle Exit and Cancer$398,520
R01 · FY2004 · AG
Proliferative effects of cdk4 and cdk6 dysregulation$283,500
R01 · FY2004 · CA
Role of pRb in Osteogenesis, Cell Cycle Exit and Cancer$421,280
R01 · FY2003 · AG
Proliferative effects of cdk4 and cdk6 dysregulation$208,490
R01 · FY2003 · CA
Proliferative effects of cdk4 and cdk6 dysregulation$85,510
R01 · FY2003 · CA
Role of pRb in Osteogenesis, Cell Cycle Exit and Cancer$31,241
R01 · FY2003 · AG
Role of pRb in Osteogenesis, Cell Cycle Exit and Cancer$344,000
R01 · FY2002 · AG
PROLIFERATIVE EFFECTS OF CDK4 AND CDK6 DYSREGULATION$277,738
R01 · FY2001 · GM
PROLIFERATIVE EFFECTS OF CDK4 AND CDK6 DYSREGULATION$269,726
R01 · FY2000 · GM